Membership is open to any person working in the pharmacogenomic and personalised medicine field, preferably, but not exclusively, based in a European country.
ESPT individual members have full access to all ESPT activities such as the restricted area on the ESPT web site, the DMPT journal and the ESPT teaching Platform. They will also benefit from reductions for courses, schools and meetings.
Annual membership fee:
- 85 €
Students under 35 years of age, including PhD students, are more than welcome in ESPT!
A special Student membership fee, which gives full access to all ESPT activities such as the restricted area on the ESPT web site, the DMPT journal, ESPT teaching Platform, as well as reductions for courses, schools and meetings, can be applied when in regular terms of studies.
Annual membership fee for students:
- 30 €
The strong link between Research Teams, Research Groups working in the field and ESPT represent the scientific image of our organization.
CRITERIA FOR ESPT MEMBERSHIP
ESPT Research groups should represent one or two relevant domains in Pharmacogenomics and Personalized Medicine.
Each group should be constituted by one (or more) leader and 10 to 30 group members.
Group leaders are recognised as full members whilst group members are considered ESPT associate members.
All members, both leaders and associate members, have full access to ESPT activities such as the restricted area on the ESPT web site, DMPT journal, ESPT teaching Platform. They will also benefit from reductions for courses, schools and meetings.
The annual membership fee:
- 20 € per associate member
- 85 € for the leader(s)
CURRENT ESPT ACTIVE RESEARCH GROUPS
For more information about the research group, please click on the name of the group.
|CANSEARCH research Laboratory||Geneva, Switzerland||Marc Ansari|
|Center for Pharmacogenomics – The Ohio State University||Columbus, USA||Wolfgang Sadee|
|Extremadura University Hospital and Medical School, Badajoz – CICAB Clinical Research Center||Badajoz, Spain||Adrian Llerena|
|Karolinska Institute – Department of Physiology and Pharmacology||Stockholm, Sweden||Magnus Ingelman-Sundberg|
|Lab Applied Molecular Biology and Pharmacogenomics – University of Sao Paulo||Sao Paulo, Brazil||Rosario Hirata|
|Labex –Institut de Biologie de Lille – CNRS UMR 8199||Lille, France||Philippe Froguel|
|Laboratoire d’hématologie – CHU Timone||Marseille, France||Pierre Morange / Marie-Christine Alessi|
|Pharmacogenetics Research Group Rotterdam||Rotterdam, The Netherlands||Ron H.N. Van Schaik|
|Pharmacogenomics laboratory – Research Center CHUQ (CHUL) – Laval University Faculty of Pharmacy||Quebec, Canada||Chantal Guillemette|
|UMR INSERM U 1122 Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire (IGE-PCV)||Nancy, France||Sophie Siest|
|University of Ljubljana, Faculty of Pharmacy research group||Ljubljana, Slovenia||Janja Marc|
|Omics Science Center – RIKEN Yokohama Institute||Yokohama, Japan||Toshihisa Ishikawa|
|Luxembourg Centre for Systems Medicine||Luxembourg||Jochen Schneider|
Pharmacogénomique des anticoagulants
|France||Marie-Anne Loriot/ Virginie Siguret / Pascale Gaussem|
|Charles Auffray||Lyon, France||Maria Nogueira|
|Leiden Academic Centre for Drug Research – Leiden University Medical Center||Leiden, The Netherlands||H.J. Guchelaar/ J.J. Swen|
|Slovakian Research Group||Slovakia||Ivan Tkac|
|IKP Stuttgart – Institut für Klinische Pharmakologie Stuttgart||Germany||Matthias Schwab|
|Institute for Pharmacology and Toxicology Center for Pharmacogenetics and Pharmacogenomics – Paracelsus Medical University||Salzburg, Austria||Markus Paulmichl|
|Centre Energie Atomique – Saclay||Gif sur Yvette, France||Isabelle Philippe|
|Department of Molecular and Clinical Pharmacology – The Wolfson Centre for Personalised Medicine – Institute of Translational Medicine – University of Liverpool||Liverpool, United Kingdom||Munir Pirmohamed|
|Department of Neurosciences, Mental Health and Sensory Organs – Sapienza University of Rome||Rome, Italy||Maurizio Simmaco|
All National Societies or corresponding networks related to pharmacogenomics that have firmly agreed to collaborate with ESPT in the name of their society can apply for ESPT membership.
CRITERIA FOR ESPT MEMBERSHIP
Each affiliated National Society will be constituted by one national representative and all the members of the society itself.
National representatives are recognised as full members whilst the society members are considered ESPT associate members.
All members, both national representatives and associate members, have full access to ESPT activities such as the restricted area on the ESPT web site, the DMPT journal, the ESPT teaching Platform. They will also benefit from reductions for courses, schools and meetings.
The annual membership fee:
- 5 € per associate member
- 85 € for the national representative
If you wish to become an ESPT affiliated National Society please write an e-mail to firstname.lastname@example.org.
CURRENT ESPT NATIONAL SOCIETIES
|Country||Name of the Society||Coordinators|
|Bulgary||BAPEMED – Bulgarian Association for Personalized Medicine||Gergana Kyosovska|
|Croatia||CSPPT – The Croatian Society of Pharmacogenomics and Personalised Therapy||Nada Božina|
|Denmark||DSPM – Danish Society for Personalised Medicine||Lona Louring Christrup|
|Finland||FSCP – Finnish Society of Clinical Pharmacology||Niemi Mikko|
|Russia||SPPT – Society of Pharmacogenetics, Pharmacokinetics and
|Country||Name of the Society||Contact|
|Austria||Austrian Network Pharmacogenomics and Personalized Medicine||Markus Paulmichl, Andrea Griesmacher|
|Belgium||Network on Pharmacogenomics and personalized medicine||Bruno Flamion,
|Bosnia Herzegovina||Bosnian Herzegovinian Network Pharmacogenomics and Personalized Medicine||Sabina Semiz|
|Bulgaria||Bulgarian Network Pharmacogenomics and Personalized Medicine||Kamen Tzatchev,
|Canada||Canadian Network Pharmacogenomics and Personalised Medicine||Chantal Guillemette|
|China||Chinese Network Pharmacogenomics and Personalized Medicine||Bing Chen,
|Cyprus||Cyprian Network Pharmacogenomics and Personalized Medicine||Spyroula Christou|
|Czech Republic||Czech Network Pharmacogenomics and Personalized Medicine||Hubacek Jaroslav, Vladimir Palicka
(long time necessary)
|Egypt||Egyptian Network Pharmacogenomics and Personalised Medicine||Soad Eltabakh|
|Estonia||Estonian Network Pharmacogenomics and Personalized Medicine||Andres Mestpalu|
|France||GPCO Unicancer – Clinical Pharmacology Oncology Group||Joseph Ciccolini|
|France||Pharmacological therapeutic follow up – Personalised treatment||Frederic Libert|
|Greece||Hellenic Society of Pharmacogenomics and Personalized Diagnosis and Therapy (EEPHARM)||Nikolaos Drakoulis,
|Germany||German Society on Pharmacogenomics and Personalized medicine||Julia Stingl,
|Hungary||Hungarian Society of Personalized Medicine||Gyorgy Némethi|
|Israel||Israeli Network Pharmacogenomics and Personalized Medicine||Mati Berkovich|
|India||Indian Network Pharmacogenomics and Personalized Medicine||Sujit Nair|
|Iran||Iranian Network Pharmacogenomics and Personalized Medicine||Majid Varatesh, Mohsen Azimi-Nezhad,
|Ireland||Irish Network Pharmacogenomics and Personalized Medicine||(Ian Young)|
|Korea||Korean Network Pharmacogenomics and Personalised Medicine||Jae-Gook Shin|
|Latvia||Latvian Network Pharmacogenomics and Personalized Medicine||Dzintars Ozolins,(Linkedin)|
|Lebanon||Lebanese Network Pharmacogenomics and Personalized Medicine||Rose T. Daher,
Said El Shamieh
|Lituania||Lituanian Network Pharmacogenomics and Personalized Medicine||Vacis Tatarunas|
|Luxemburg||Luxemburger Network Pharmacogenomics and Personalized Medicine||Udo Margraff|
|Malta||Maltan Network Pharmacogenomics and Personalized Medicine||Anthony Fenech|
|Netherlands||Network on Pharmacogenomics and personalized medicine||Ron H. N. van Schaik|
|Norway||Norwegian Network Pharmacogenomics and Personalized Medicine||Ann-Helen Kristoffersen,
Sverre Sandberg – EFLM
|Poland||Polish Network Pharmacogenomics and Personalized Medicine||Iwona Wybranska|
|Portugal||Portuguese Network Pharmacogenomics and Personalized Medicine||Rui Medeiros,
Helder Mota-Filipe, J.T. Guimaraes
|Romania||Romanian Network Pharmacogenomics and Personalized Medicine||Ioana Brudașcă|
|Serbia||Serbian Society of Pharmacogenomics and Theranostics||Sanja Stankovic|
|Slovakia||Slovakian Network Pharmacogenomics and Personalized Medicine||Ivan Tkac|
|Slovenia||Slovenian Network Pharmacogenomics and Personalized Medicine||Janja Marc,
Natasa Karas Kuzelicki
|South Africa||South African Network Pharmacogenomics and Personalized Medicine||Vanessa Steenkamp, Mongi Benjeddou|
|Spain||Spanish Society of Pharmacogenetics and Pharmacogenomics||Taron Miquel|
|Sweden||Swedish Network Pharmacogenomics and Personalized Medicine||Elvar Theodorsson,
|Switzerland||The Swiss group of Pharmacogenomics and Personalized Medicine||Marc Ansari, Hugo Kupferschmidt|
|Turkey||Turkish Society for Pharmacogenomics and Personalized Thérapy||Belgin Süsleyici Duman|
Any company involved in the field of pharmaceutics, biotechnology, laboratory medicine or related disciplines may become a ESPT corporate member.
CRITERIA FOR ESPT MEMBERSHIP
ESPT Corporate Members will be involved in ESPT corporate members meetings to discuss topics of interest and strategy of the Society.
They will be enlisted in the dedicated area of the ESPT web site and they will also benefit from special fees at ESPT events (National Congresses as well as Summer Schools).
Corporate membership is €1.250 per year with a minimum of 2 years subscription.
Companies can apply for ESPT membership by writing an e-mail to
European Institutional collaborators
We are cooperating with the following European Institutional members to avoid overlapping and to reinforce the translation of Pharmacogenomics into clinical practice.
|EFLM – European Federation of Clinical Chemistry and Laboratory Medicine||Mauro Panteghini|
|EPHAR – Federation of European Pharmacological Societies||Thomas Griesbacher|
|ESF – European Science Foundation||Kirsten Steinhausen|
|EDMA – European Diagnostic Manufacturers Association||Serge Bernasconi|
|EUSPM – European Society of Predictive Medicine||Maurizio Ferrari|
We are in discussion with:
|EHA -European Association of Hematologists||Christine Chomienne|
|EFPIA – European Federation of Pharmaceutical Industries and Associations||Magda Chlebus|
|ESCP – European Society of Clinical Pharmacy||Olivier Bourdon/J. Swen|
|EACPT – European Association for Clinical Pharmacology and Therapeutics||Simon Tabassome|
|EAPM – The Europe Alliance for Personalised Medicine||Denis Horgan|
|EUPATI – European Patients Academy||Ingrid Klingmann|
We have also good contacts with other European organizations particularly:
|EMA – European Medicines Agency||Marisa Papaluca|
|IMI –Innovative Medicines Initiative||Magda Gunn|
|ESHG – European Society of Human Genetics||Jerome del Picchia|
|ESBB – European, Middle Eastern and African Society for Biopreservation and Biobanking||Robert Hewitt|
|EPEMED – European Personalized Medicine Association||Alain Huriez|
|EUFEPS – European Federation for Pharmaceutical Sciences||Meindert Danhof|
International Institutional collaborators
We are cooperating with the following International Institutional members to avoid overlapping and to reinforce the translation of Pharmacogenomics into clinical practice:
|IFCC – International Federation of Clinical Chemistry and Laboratory Medicine||Maurizio Ferrari|
|IUPHAR – International Union of Basic and Clinical Pharmacology – Pharmacogenomics Subgroup||Guilherme Kurtz-Suarez|
We have also good contacts with other International organisations particularly:
|ISSX – International Society for the Study of Xenobiotics||John Miners|
|IATDMCT – International Association of Therapeutic Drug Monitoring and Clinical Toxicology||Pierre Wallemacq|
|ISNN – International Society of Nutrigenetics/Nutrigenomics||Alfredo Martinez|
|FIP – International Pharmaceutical Federation||Bernard Poggi|